INDP:NASDAQIndaptus Therapeutics, Inc. Analysis

Indaptus Therapeutics is trading well above its short‑term moving averages, with the 20‑day SMA above the 50‑day SMA, supporting a bullish trend despite a neutral RSI near the midpoint. The MACD histogram is negative and the signal line is bearish, indicating short‑term momentum weakness, while volume has been trending lower, suggesting waning buying pressure. The stock’s beta is markedly high, reflecting amplified price swings, and 30‑day volatility is extreme, placing the equity in a high‑risk profile. Fundamentals are weak: the company reports zero revenue, negative earnings per share, and sizable cash burn, while valuation multiples such as price‑to‑book are astronomically high, implying significant overvaluation. Recent news mentions the release of new clinical data, which could be a catalyst, but the material remains limited and unverified. Overall, the technical picture shows a bullish longer‑term trend constrained by bearish short‑term signals and a precarious financial foundation.